CorMedixCRMD
Market Cap: $322M
About: Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets.
Employees: 82
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
89% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 9
68% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 22
9% more funds holding
Funds holding: 90 [Q1] → 98 (+8) [Q2]
0% more capital invested
Capital invested by funds: $74M [Q1] → $74.2M (+$115K) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
0.6% less ownership
Funds ownership: 31.77% [Q1] → 31.17% (-0.6%) [Q2]
80% less call options, than puts
Call options by funds: $305K | Put options by funds: $1.55M
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
Rodman & Renshaw Brandon Folkes 50% 1-year accuracy 4 / 8 met price target | 126%upside $13 | Buy Initiated | 26 Aug 2024 |
Needham Serge Belanger 41% 1-year accuracy 47 / 114 met price target | 74%upside $10 | Buy Reiterated | 15 Aug 2024 |
Truist Securities Joon Lee 62% 1-year accuracy 28 / 45 met price target | 108%upside $12 | Buy Maintained | 25 Jul 2024 |
Needham Serge Belanger 41% 1-year accuracy 47 / 114 met price target | 74%upside $10 | Buy Reiterated | 19 Jun 2024 |
Financial journalist opinion
Based on 6 articles about CRMD published over the past 30 days